West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc.

WST

$407.88

Updated: 03/11/2026, 05:29:52

Market Cap
$28.41B
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US

No historical data available

Company Profile

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

USD
NYSE
CEO: Michel Lagarde
Employees: 10,800
https://www.westpharma.com
Asset Summaries
Latest generated summaries for WST

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
WST-10-k-fy2025.html2.6 MBtext/htmlENFiled 17/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 70 KPI observations

Revenue

$3.1B

FY 2025 · Reported

Net income

$0.5B

FY 2025 · Reported

Gross margin

35.9%

FY 2025 · Calculated

Free cash flow

$0.5B

FY 2025 · Calculated

R&D intensity

2.4%

FY 2025 · Calculated

Share repurchases

$0.1B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Contract-Manufactured Products segment offering
Proprietary Products segment offering
Proprietary Products portfolio
Contract-Manufactured Products portfolio

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
4 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Asia manufacturing network

Asia · Manufacturing Partner Country

95% confidence
Functions
Manufacturing, Supply Chain
Ownership
Outsourcing Partner
Products / scope
Not disclosed by country
Share of production
Not disclosed by country
Reported revenue share
Not disclosed by country
Manufacturing footprint. This reportable segment has manufacturing facilities in North and South America, Europe, and Asia, with affiliated companies in Japan and Mexico.

Asia

Asia manufacturing network

This reportable segment has manufacturing facilities in North and South America, Europe, and Asia, with affiliated companies in Japan and Mexico.

Europe

Europe manufacturing network

This reportable segment has manufacturing facilities in North America and Europe.

North America

North America manufacturing network

This reportable segment has manufacturing facilities in North America and Europe.

North and South America

North and South America manufacturing network

This reportable segment has manufacturing facilities in North and South America, Europe, and Asia, with affiliated companies in Japan and Mexico.

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Core business

Global manufacturer of containment and delivery systems for injectable drugs

98%
Source evidence
“We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products.”

Business overview

Leading global manufacturer of integrated containment and delivery systems for injectable drugs and healthcare products

98%
Source evidence
“We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products.”

Two global operating segments

Two global segments: Proprietary Products and Contract-Manufactured Products

98%
Source evidence
“Our business operations are organized into two global segments, Proprietary Products and Contract-Manufactured Products.”

Two reportable segments

Proprietary Products and Contract-Manufactured Products

98%
Source evidence
“Our business operations are organized into two global business segments, Proprietary Products and Contract-Manufactured Products.”

Goodwill by segment 2025

Goodwill at Dec 31, 2025: Proprietary Products $80.0M, Contract-Manufactured Products $29.9M, Total $109.9M

95%
Source evidence
“Balance, December 31, 2025$80.0 $29.9 $109.9”

Reportable segments

Two reportable segments: Proprietary Products and Contract-Manufactured Products

95%
Source evidence
“The changes in the carrying amount of goodwill by reportable segment were as follows: ($ in millions)Proprietary ProductsContract-Manufactured ProductsTotal”

Customer base

Leading biologic, generic, pharmaceutical, diagnostic, and medical device companies

96%
Source evidence
“Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies in the world.”

Customer base

Customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies around the world

96%
Source evidence
“Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies around the world.”

Sales and distribution model

Primarily own sales force and distribution network; limited contract agents and regional distributors

90%
Source evidence
“Our products and services are sold and distributed primarily through our own sales force and distribution network, with limited use of contract sales agents and regional distributors.”

Contract-Manufactured Products segment offering

Contract-manufactured segment: fully integrated design, manufacture and automated assembly of complex devices for pharma, diagnostic and medical device customers

97%
Source evidence
“Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.”

Proprietary Products segment offering

Proprietary segment offers packaging, containment, drug delivery systems, lab services primarily to biologic, generic and pharmaceutical drug customers

97%
Source evidence
“Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers.”

Proprietary Products portfolio

Elastomers & primary containment, drug delivery devices, integrated systems, analytical lab services

97%
Source evidence
“Our Proprietary Products reportable segment offers elastomers & primary containment, drug delivery devices, integrated systems, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers.”

Contract-Manufactured Products portfolio

Design, manufacture and automated assembly of complex devices using molding, welding and clean room technologies

95%
Source evidence
“focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.”

Sales outside the U.S.

56.7% of consolidated net sales in 2025 were outside the U.S.

97%
Source evidence
“Sales outside of the U.S. accounted for 56.7% of our consolidated net sales in 2025.”

Net sales by segment 2025 vs 2024 vs 2023

FY2025: Proprietary $2,492.1M (+6.8%); Contract-Manufactured $582.0M (+4.2%); Consolidated $3,074.1M (+6.3%)

99%
Source evidence
“Proprietary Products$2,492.1 $2,334.5 $2,397.3 6.8%(2.6%) Contract-Manufactured Products582.0 558.7 552.5 4.2%1.1% Consolidated net sales$3,074.1 $2,893.2 $2,949.8 6.3%(1.9%)”

Operations and dependencies

Three primary raw materials

Elastomers, aluminum and plastic; reliance on single-source suppliers for certain critical raw materials

95%
Source evidence
“We use three primary raw materials in the manufacture of our products: elastomers, aluminum and plastic.”

FX translation impact on 2025 sales

2025 consolidated sales up $180.9M (6.3%), incl. favorable FX of $56.4M; +4.3% ex-FX

97%
Source evidence
“Consolidated net sales increased by $180.9 million, or 6.3%, in 2025, including a favorable foreign currency translation impact of $56.4 million. Excluding foreign currency translation effects, consolidated net sales increased by $124.5 million, or 4.3%.”

Manufacturing footprint

Proprietary: Americas, Europe, Asia (affiliates in Japan, Mexico); Contract: North America and Europe

93%
Source evidence
“This reportable segment has manufacturing facilities in North and South America, Europe, and Asia, with affiliated companies in Japan and Mexico.”

Daikyo distributorship dependency

Majority of $122.6M 2025 affiliate purchases relate to a distributorship agreement with Daikyo to purchase and re-sell Daikyo products

90%
Source evidence
“The majority of the purchase transactions listed above relate to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products.”

Single-source supplier reliance

Relies on single-source suppliers for certain critical raw materials

93%
Source evidence
“we rely on single-source suppliers for certain critical raw materials.”

Positioning and strategy

Equity method affiliates

Five 49%-owned equity method affiliates (4 in Mexico, Daikyo Seiko in Japan); total investments in affiliates $212.3M at Dec 31, 2025

95%
Source evidence
“Daikyo Seiko, Ltd. ("Daikyo") Japan49%”

Capital expenditures trend

Capital expenditures: $285.9M (2025), $377.0M (2024), $362.0M (2023)

95%
Source evidence
“Capital expenditures(285.9)(377.0)(362.0)”

Named competitors in Proprietary Products

Competes with Datwyler and Aptar in Proprietary Products lines

94%
Source evidence
“we compete with several companies, such as Datwyler and Aptar, across our Proprietary Products product lines.”

SmartDose 3.5mL sale to AbbVie

Agreement to sell SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie; $8.4M charges in 2025

95%
Source evidence
“During 2025, the Company recorded charges of $8.4 million related to the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie.”

R&D investment areas

R&D focused on elastomeric packaging, formulation development, integrated drug containment systems, self-injection systems and drug administration consumables

94%
Source evidence
“additional investments in our elastomeric packaging components, formulation development, integrated drug containment systems, self-injection systems and drug administration consumables”

Risks, financing, and outlook

Restructuring charges 2025

2025 restructuring and other charges of $23.3M pre-tax across two existing restructuring programs

95%
Source evidence
“During 2025, the Company recorded pre-tax charges of $23.3 million related to our two existing restructuring programs”

Cost of goods sold drivers

COGS driven by personnel, manufacturing, raw materials, freight, depreciation and facility costs, plus inflation

92%
Source evidence
“Fluctuations in our cost of goods sold correspond with the fluctuations in sales units as well as inflationary and other market factors that influence our cost base.”

Inflation and commodity price exposure

Open-market commodity purchases expose results to price fluctuations and inflation-driven raw material costs

90%
Source evidence
“We purchase certain raw materials in the open commodities market and therefore the results of our operations may be affected by price fluctuations.”

Long-term debt composition

Total debt $202.8M net: Term Loan due July 2, 2027 (5.02%) $130.0M and Series C notes due July 5, 2027 (4.02%) $73.0M

95%
Source evidence
“Term Loan, due July 2, 2027 (5.02%) $130.0 $130.0 Series C notes, due July 5, 2027 (4.02%) 73.0 73.0”

Revolving credit facility

$500.0M senior unsecured multi-currency revolver expiring March 2027; expandable by the greater of $929.0M or trailing twelve-month EBITDA

90%
Source evidence
“a $500.0 million senior unsecured revolving credit facility by entering into a Second Amendment and Joinder and Assumption Agreement (the "Amended Credit Agreement"). The Amended Credit Agreement, which expires March 2027”

Sales drivers and pricing

Net sales affected by mix, pricing realization, order timing, regulatory actions, competition and acquisitions

90%
Source evidence
“Several factors affect our reported net sales in any period, including product, payer and geographic sales mix, operational effectiveness, pricing realization, timing of orders and shipments, regulatory actions, competition, and business acquisitions”

Data privacy regulation (GDPR/CCPA)

Subject to EU/UK GDPR and California CCPA/CPRA data privacy regimes

95%
Source evidence
“the European Union's General Data Protection Regulation (the "EU GDPR"), the United Kingdom's GDPR (the "UK GDPR") and California's Consumer Privacy Act of 2018”

Tariffs and trade restrictions

US-imposed tariffs and retaliatory restrictions monitored; impact was not material to 2025 results

95%
Source evidence
“In recent months, the U.S. government has imposed additional tariffs and trade restrictions on certain goods produced outside of the United States... Based on the information available at this time, the impact was not material to our 2025 results.”

Health regulators

Products regulated by FDA, EMA, and China NMPA

94%
Source evidence
“subject to regulation by governmental authorities in the U.S., Europe and other countries, including the U.S. Food and Drug Administration ("FDA"), the European Medicines Agency and the National Medical Products Administration (China).”

PFAS packaging restrictions

PFAS restriction regulations in EU and U.S. states could affect packaging products

90%
Source evidence
“the European Union and some states in the United States have introduced, and are considering more comprehensive updates to, regulations aimed at restricting the use of per and polyfluoroalkyl substances ("PFAS") in packaging”

Dependence on injectable drug delivery (GLP-1s)

Business depends substantially on injectable drug delivery, e.g., GLP-1s; oral alternatives or reduced dosing frequency pose demand risk

97%
Source evidence
“Our business depends to a substantial extent on customers' continued sales and development of products that are delivered by injection, such as GLP-1s.”

Macroeconomic and supply chain risk

Global economic downturns, inflation and supply chain disruptions could reduce demand and raise costs

93%
Source evidence
“heightened inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession, may result in unfavorable conditions”

Pharma/healthcare customer consolidation

Customer consolidation and GPO purchasing concentration create pricing pressure

93%
Source evidence
“group purchasing organizations and integrated health delivery networks have served to concentrate purchasing decisions for some customers, which has placed pricing pressure on suppliers”

Cybersecurity risk

Cyberattack exposure across own and third-party systems

92%
Source evidence
“Our systems and networks, as well as those of our customers, suppliers, service providers, and banks, have and may in the future become the target of cyberattacks”

Climate regulation and extreme weather risk

Climate change regulation (notably EU) and extreme weather pose cost and demand risks

92%
Source evidence
“These types of extreme weather events have and may continue to adversely impact us, raw material availability, our suppliers, our customers and their ability to purchase our products”

Reimbursement / healthcare cost containment

Third-party payer reimbursement changes and cost containment could affect product demand and pricing

90%
Source evidence
“Our sales depend, in part, on the extent to which healthcare providers and facilities are reimbursed by government authorities (including Medicare, Medicaid and comparable foreign programs) and private insurers”

Banking/liquidity counterparty risk

Bank failure could impair access to cash and liquidity

90%
Source evidence
“Potential future disruptions in access to bank deposits or lending commitments due to bank failure could materially and adversely affect our liquidity”

Material exposure graph

Pharmaceutical companies (injectable/GLP-1 drug makers)
Customer Exposure

Sales and profitability largely depend on customers' continued sale and development of injectable drug products such as GLP-1s.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“Our business depends to a substantial extent on customers' continued sales and development of products that are delivered by injection, such as GLP-1s.”
Biologic, generic and pharmaceutical drug companies
Revenue Exposure

Proprietary Products segment sales are driven primarily by biologic, generic and pharmaceutical drug customers.

Relevance 92·Dependency 85·Confidence 95
Source evidence
“primarily to biologic, generic and pharmaceutical drug customers”
Biologic, generic and pharmaceutical drug companies
Customer Exposure

Proprietary Products are sold primarily to biologic, generic and pharmaceutical customers whose injectable drug production drives demand; top-10 customers were 47.6% of 2025 net sales with one customer at 15.8%.

Relevance 92·Dependency 80·Confidence 95
Source evidence
“offers elastomers & primary containment, drug delivery devices, integrated systems, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers”
Injectable drug containment and delivery systems
Demand Driver

Order and shipment timing and regulatory actions are disclosed as key drivers of net sales for the containment/delivery product portfolio.

Relevance 90·Dependency 80·Confidence 90
Source evidence
“including product, payer and geographic sales mix, operational effectiveness, pricing realization, timing of orders and shipments, regulatory actions, competition”
Elastomers
Supplier Dependency

Elastomers (synthetic and natural) are a primary raw material; single-source supplier reliance for certain critical raw materials creates supply interruption risk.

Relevance 80·Dependency 78·Confidence 90
Source evidence
“we rely on single-source suppliers for certain critical raw materials.”
FDA, EMA and China NMPA regulation
Regulatory Exposure

Product design, development, manufacturing, marketing and labeling are regulated by FDA, EMA and NMPA; regulatory oversight can impact time and cost of product development and continued availability.

Relevance 78·Dependency 70·Confidence 92
Source evidence
“Regulatory authorities, including regulatory review and oversight, can impact on the time and cost associated with the development and continued availability of our products”
Pharmaceutical, diagnostic, and medical device companies
Customer Exposure

Contract-Manufactured Products segment demand comes primarily from pharmaceutical, diagnostic, and medical device customers.

Relevance 78·Dependency 60·Confidence 92
Source evidence
“focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers”
Foreign currency fluctuations
Currency Exposure

Majority of sales generated internationally with local functional currencies; FX volatility affects results, partially mitigated by hedging.

Relevance 75·Dependency 70·Confidence 92
Source evidence
“fluctuations in foreign currency exchange rates affect the results of our operations and the value of our foreign assets and liabilities”
Pharmaceutical, diagnostic and medical device companies
Customer Exposure

Contract-Manufactured Products segment serves pharmaceutical, diagnostic and medical device customers who incorporate West components into their manufacturing lines.

Relevance 75·Dependency 65·Confidence 90
Source evidence
“Our Contract-Manufactured Products customers include many of the world's largest pharmaceutical, diagnostic, and medical device companies.”
Daikyo Seiko, Ltd.
Supplier Dependency

West depends on its 49%-owned affiliate Daikyo via a distributorship agreement that accounts for the majority of affiliate purchases ($122.6M in 2025) of products West re-sells.

Relevance 75·Dependency 60·Confidence 90
Source evidence
“The majority of the purchase transactions listed above relate to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products.”
US Dollar
Currency Exposure

FX translation materially affects reported sales; subsidiaries with non-USD functional currency contributed $56.4M favorable translation in 2025.

Relevance 72·Dependency 55·Confidence 95
Source evidence
“including a favorable foreign currency translation impact of $56.4 million”
US tariffs and trade restrictions
Regulatory Exposure

US-imposed tariffs and retaliatory foreign restrictions on goods create cost and demand uncertainty; company monitors and reported no material 2025 impact.

Relevance 70·Dependency 40·Confidence 93
Source evidence
“We continue to monitor this dynamic situation to assess the impact of these tariffs on our business and actions we can take to minimize their impact.”
Aluminum
Raw Material Dependency

Aluminum is one of three primary raw materials used in manufacturing; purchased partly in the open commodities market, creating price-fluctuation exposure.

Relevance 65·Dependency 65·Confidence 88
Source evidence
“We use three primary raw materials in the manufacture of our products: elastomers, aluminum and plastic.”
Global economic conditions
Demand Driver

Downturns, inflation and supply chain disruptions could reduce demand via customer destocking and raw material shortages.

Relevance 65·Dependency 60·Confidence 88
Source evidence
“Those conditions could negatively affect demand for our products due to customers decreasing their inventories in the near-term or long-term”
Inflation
Cost Driver

Inflationary and other market factors influence the cost base and gross profit.

Relevance 65·Dependency 50·Confidence 88
Source evidence
“as well as inflationary and other market factors that influence our cost base”
Aptar
Competitive Exposure

Aptar is a named competitor across Proprietary Products lines.

Relevance 65·Dependency 45·Confidence 90
Source evidence
“we compete with several companies, such as Datwyler and Aptar, across our Proprietary Products product lines.”
Datwyler
Competitive Exposure

Datwyler is a named competitor across Proprietary Products lines; competition based on design/performance, quality, regulatory compliance, scientific expertise and total cost.

Relevance 65·Dependency 45·Confidence 90
Source evidence
“we compete with several companies, such as Datwyler and Aptar, across our Proprietary Products product lines.”
Plastic
Raw Material Dependency

Plastic is one of three primary raw materials; commodity-market purchases expose results to price fluctuations and inflation.

Relevance 60·Dependency 60·Confidence 88
Source evidence
“We purchase certain raw materials in the open commodities market and therefore the results of our operations may be affected by price fluctuations.”
PFAS packaging regulations
Regulatory Exposure

EU and U.S. state restrictions on PFAS in packaging could require alternative materials and affect results.

Relevance 60·Dependency 55·Confidence 88
Source evidence
“Such regulations restricting or banning PFAS could adversely affect our business and results of operations”
EU/UK GDPR and CCPA/CPRA
Regulatory Exposure

Data privacy compliance obligations worldwide with risk of fines, investigations and processing restrictions.

Relevance 60·Dependency 55·Confidence 93
Source evidence
“we must comply with increasingly complex and rigorous, and sometimes conflicting laws, regulatory standards”
Competition
Competitive Exposure

Competition is disclosed as one of the factors affecting reported net sales in any period.

Relevance 60·Dependency 45·Confidence 85
Source evidence
“regulatory actions, competition, and business acquisitions that involve our customers or competitors”
Third-party payer reimbursement
Demand Driver

Reimbursement levels by Medicare, Medicaid, foreign programs and private insurers influence customer demand and prices.

Relevance 55·Dependency 50·Confidence 85
Source evidence
“Reimbursement rates can also affect the market acceptance rate of new technologies and products.”
Climate change / extreme weather
Raw Material Dependency

Extreme weather has impacted and may impact raw material availability, suppliers, customers, manufacturing and transport; new climate regulations could raise costs.

Relevance 55·Dependency 50·Confidence 85
Source evidence
“increase the frequency or severity of extreme weather events, including droughts, hurricanes, wildfires and flooding”
USD
Currency Exposure

Foreign currency translation adjustments of $149.2M in 2025 (vs -$112.3M in 2024) materially swing comprehensive income, indicating meaningful non-USD exposure.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“Foreign currency translation adjustments, net of tax of $0.0, $3.6, and $1.0 149.2 (112.3)39.4”
AbbVie
Revenue Exposure

Divestiture counterparty for the SmartDose 3.5mL On-Body Delivery System and associated facilities; $8.4M in charges recorded in 2025.

Relevance 55·Dependency 30·Confidence 90
Source evidence
“the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie”
Full company information
Latest profile, trading, valuation, and identifier data stored for WST.
Share price
$407.88
Market cap
$28.41B
Exchange
NYSE
Currency
USD
CEO
Michel Lagarde
Employees
10,800
IPO date
17/03/1980
Beta
1.125
Last dividend
$0.00
Day range
$407.32 – $418.50
52-week range
$223.83 – $438.27
1-day performance
-1.15%
1-year performance
82.23%
Current drawdown (1Y)
-6.93%
CIK
0000105770
CUSIP
955306105
ISIN
US9553061055
Created
07/12/2025, 15:08:04
Last update
03/11/2026, 05:29:52

Track West Pharmaceutical Services, Inc. with an AI analyst

See which prediction-market events move WST, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to WST from your Railway `news_articles` table.

West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Seeking Alpha • STOCK • 02/06/2026, 21:11:53

West Appoints Michel Lagarde to be President and Chief Executive Officer

PRNewsWire • STOCK • 01/06/2026, 18:30:00

West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast

Reuters • STOCK • 20/05/2026, 19:24:42

West Pharma says operations recovering after cyberattack

Reuters • STOCK • 15/05/2026, 16:17:56

West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 12/05/2026, 23:10:43

West Pharmaceutical Services, Inc. (WST) Hit a 52 Week High, Can the Run Continue?

Zacks Investment Research • STOCK • 11/05/2026, 12:16:33

West Pharmaceutical Services (WST) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Investment Research • STOCK • 07/05/2026, 12:55:30

West Pharmaceutical: Multiple Growth Drivers Are A Tailwind

Seeking Alpha • STOCK • 30/04/2026, 20:41:08

Are You Looking for a Top Momentum Pick? Why West Pharmaceutical Services (WST) is a Great Choice

Zacks Investment Research • STOCK • 29/04/2026, 15:00:51

West Pharmaceutical (WST) Upgraded to Strong Buy: Here's What You Should Know

Zacks Investment Research • STOCK • 29/04/2026, 15:00:30

From Slide to Surge: How West Pharmaceutical Services Reclaimed Its Mojo in 2026

24/7 Wall Street • STOCK • 28/04/2026, 10:15:52

West to Participate in Upcoming Investor Conferences

PRNewsWire • STOCK • 28/04/2026, 08:00:00